Immunogenicity and safety of the non-typable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine administered following the recombinant zoster vaccine versus administration alone: Results from a randomized, phase 2a, non-inferiority trial

• Main Authors: Ilaria Galgani (Author), Airi Põder (Author), Rain Jõgi (Author), Veli-Jukka Anttila (Author), Stefano Milleri (Author), Alberto M. Borobia (Author), Odile Launay (Author), Marco Testa (Author), Daniela Casula (Author), Luca Grassano (Author), Annaelisa Tasciotti (Author), Marie Dozot (Author), Ashwani K. Arora (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A candidate AS01-adjuvanted vaccine containing four surface proteins from non-typable Haemophilus influenzae and Moraxella catarrhalis (NTHi-Mcat) has been developed to help prevent exacerbations of chronic obstructive pulmonary disease (COPD). Sequential administration of different vaccines contain...